Media

Amniotics presents at Aktiedagen in Gothenburg

News

May 11, 2023

Amniotics AB’s (publ) (Nasdaq Stockholm: AMNI) CEO Marcus Larsson will present the company at Aktiedagen in Gothenburg Monday May 15, 2023. The event is arranged by Aktiespararna

The event may be viewed live via Senaste | Aktiespararna.

For more information please contact

Marcus Larsson
CEO, Amniotics AB
Phone: +46 (0) 763 0840 91
Email: ml@amniotics.com

About Amnioitics

Amniotics AB (publ) is a clinical stage biotech company, developing innovative therapies, based on amniotic fluid derived stem cells. The company develops therapies to treat diseases where effective treatments are currently lacking.
Amniotics has an established GMP-facility, approved and licensed by the Swedish Medical Products Agency. The company has capabilities as a Contract Development and Manufacturing Organization (CDMO) for other biotech companies.
Amniotics is headquartered in Lund, Sweden.
The company is listed at Nasdaq First North Growth Market in Stockholm. Amniotics Certified Adviser at First North is Redeye AB, e post: certifiedadviser@redeye.se.
Learn more at www.amniotics.com. 

Upcoming events

Read more

Subscribe